Friday, July 10, 2026

pharma · Psoriasis Vulgaris · Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.

LEO Pharma US

LEO Pharma A/S is a pharma organization headquartered in Ballerup, DK. Primary therapeutic focus areas include Psoriasis Vulgaris, Moderate-to-severe plaque psoriasis and a body weight ≥120 kg., Mild to severe palmoplant

Madison, USA HQ
1908 Founded
75 Employees
EMA registrant Type
Company details
Status
Public
HQ
Madison, USA
Founded
1908
Employees
75
Programs
7
Drugs
11
Patents
0
Clinical program

LP0189-2318

Phase 1 · other · Gout flares

LP0189-2318 for Gout flares is a Phase 1 program (other) at LEO Pharma A/S with 1 ClinicalTrials.gov record(s).

Internal code LP0189-2318

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
LEO Pharma A/S
Phase
Phase 1
Modality
other
Indication
Gout flares
Status
active
Trials
1